Overview
Status
Active
Registry date
2019-11-18
Share capital
50,000.00 PLN
Registered address
ul. Henryka Arciucha 2, 24-100 Puławy, Poland
Website
Electronic delivery address
AE:PL-45094-11701-DSIIH-23
Financials
Revenue history (in k)
Filing timeliness
1 of 6 financial statements was filed late (for 2021, 91 days late).
- 202514/07/2026
- 202414/07/2025
- 202315/07/2024
- 202215/07/2023
- 202114/10/2022
- 202015/10/2021
Filed on timeDelayFiling deadline
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
Revenue
This companyUSD 5.78kMedianUSD 917.74kAverageUSD 25.73m
Net profit
This companyUSD 4.07kMedianUSD 14.44kAverageUSD 2.75m
Operating costs
This companyUSD 1.26kMedianUSD 860.03kAverageUSD 21.34m
Assets
This companyUSD 132.30kMedianUSD 883.09kAverageUSD 31.39m
Industry
Authorized Representatives
Tomasz Kalwat – President of the Management Board
Manner of representation
Each member of the management board is authorized to make declarations on behalf of the company independently.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Justyna Małgorzata Kalwatage 48 | 500 | $6,753.11 | 50% |
Tomasz Kalwatage 49 | 500 | $6,753.11 | 50% |
Justyna Małgorzata Kalwat and Tomasz Kalwat hold a combined 100% – the ownership structure indicates family control.
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 2019-12-31.
Debt
No entries in the National Debtors Register (KRZ).
Public aid
No public aid cases recorded in the last 10 years.
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Przedsiębiorstwo Farmaceutyczne Leki Natury Tadeusz Polańskisp. z o.o. | $893,738.50 | lekinatury.pl | ||
| LideoS.A. | $95,067.91 | lideo.tech | ||
| Munar PharmaS.A. | $85,649.72 | munar.pl | ||
| BIO Animalisp. z o.o. | $49,176.96 | proanimali.com | ||
| Ampliconsp. z o.o. | $48,330.99 | amplicon.pl | ||
| Xenira Pharmaceuticalssp. z o.o. | $26,670.82 | xenirapharma.com | ||
| Sanford Biotechsp. z o.o. | $2,586.64 | sanfordbiotech.com | ||
| Cefeasp. z o.o. | $294.66 | cefea.pl | ||
| Auxilius PharmaS.A. | $0.83 | auxiliuspharma.com | ||
| Powerpharmasp. z o.o. | – | powerpharma.eu |
FAQ
The main business activity of Polar Snuss focuses on manufacture of pharmaceutical preparations.
The company was registered in the Polish National Court Register (KRS) on November 18, 2019.
The headquarters is located at: ul. Henryka Arciucha 2, 24-100 Puławy.
The share capital of the company is PLN 50,000 (approx. $13,506).
The latest available financial statement covers the period from January 1, 2025 to December 31, 2025.
In 2025, the company generated total revenue of $5,776.
Yes, in 2025 the company achieved a net profit of $4,068.
The largest operating cost category falls under external services. This category amounted to $796 in 2025, representing 63% of all operating expenses.
Last updated: 2026-10-07
